Kostas Biliouris
Stock Analyst at Oppenheimer
(1.16)
# 3,755
Out of 5,182 analysts
66
Total ratings
37.04%
Success rate
-16.34%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kostas Biliouris
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Reiterates: Outperform | $37 | $20.98 | +76.36% | 10 | Mar 19, 2026 | |
| PRME Prime Medicine | Initiates: Outperform | $11 | $3.67 | +199.73% | 2 | Mar 12, 2026 | |
| PEPG PepGen | Initiates: Outperform | $15 | $1.60 | +837.50% | 1 | Feb 25, 2026 | |
| KRRO Korro Bio | Upgrades: Outperform | $22 | $12.84 | +71.34% | 4 | Jan 28, 2026 | |
| CNTA Centessa Pharmaceuticals | Maintains: Outperform | $40 → $62 | $39.51 | +56.92% | 7 | Dec 10, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $450 → $470 | $308.51 | +52.35% | 6 | Sep 8, 2025 | |
| IONS Ionis Pharmaceuticals | Upgrades: Outperform | $40 → $70 | $72.23 | -3.09% | 3 | Sep 3, 2025 | |
| JSPR Jasper Therapeutics | Downgrades: Market Perform | $15 → $4 | $0.93 | +330.15% | 1 | Jul 8, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Outperform | $30 → $8 | $3.49 | +129.23% | 2 | May 28, 2025 | |
| DYN Dyne Therapeutics | Initiates: Outperform | $50 | $18.04 | +177.16% | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $25 | $7.82 | +219.69% | 2 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $50 | $13.04 | +283.44% | 6 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $34 | $7.03 | +383.64% | 3 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $22 → $17 | $1.49 | +1,044.78% | 2 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $40 | $9.45 | +323.28% | 4 | Jul 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 | $23.65 | +280.55% | 3 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 | $29.17 | +95.44% | 3 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $37 | $74.52 | -50.35% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $102 → $100 | $53.81 | +85.86% | 4 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $98 | $50.99 | +92.19% | 1 | Jun 17, 2022 |
Sarepta Therapeutics
Mar 19, 2026
Reiterates: Outperform
Price Target: $37
Current: $20.98
Upside: +76.36%
Prime Medicine
Mar 12, 2026
Initiates: Outperform
Price Target: $11
Current: $3.67
Upside: +199.73%
PepGen
Feb 25, 2026
Initiates: Outperform
Price Target: $15
Current: $1.60
Upside: +837.50%
Korro Bio
Jan 28, 2026
Upgrades: Outperform
Price Target: $22
Current: $12.84
Upside: +71.34%
Centessa Pharmaceuticals
Dec 10, 2025
Maintains: Outperform
Price Target: $40 → $62
Current: $39.51
Upside: +56.92%
Alnylam Pharmaceuticals
Sep 8, 2025
Maintains: Outperform
Price Target: $450 → $470
Current: $308.51
Upside: +52.35%
Ionis Pharmaceuticals
Sep 3, 2025
Upgrades: Outperform
Price Target: $40 → $70
Current: $72.23
Upside: -3.09%
Jasper Therapeutics
Jul 8, 2025
Downgrades: Market Perform
Price Target: $15 → $4
Current: $0.93
Upside: +330.15%
Rocket Pharmaceuticals
May 28, 2025
Maintains: Outperform
Price Target: $30 → $8
Current: $3.49
Upside: +129.23%
Dyne Therapeutics
Mar 12, 2025
Initiates: Outperform
Price Target: $50
Current: $18.04
Upside: +177.16%
Mar 4, 2025
Maintains: Outperform
Price Target: $67 → $25
Current: $7.82
Upside: +219.69%
Jan 10, 2025
Maintains: Outperform
Price Target: $70 → $50
Current: $13.04
Upside: +283.44%
Jan 10, 2025
Upgrades: Outperform
Price Target: $34
Current: $7.03
Upside: +383.64%
Aug 15, 2024
Maintains: Outperform
Price Target: $22 → $17
Current: $1.49
Upside: +1,044.78%
Jul 18, 2024
Maintains: Outperform
Price Target: $63 → $40
Current: $9.45
Upside: +323.28%
Jul 3, 2024
Maintains: Outperform
Price Target: $90
Current: $23.65
Upside: +280.55%
Mar 27, 2024
Maintains: Outperform
Price Target: $57
Current: $29.17
Upside: +95.44%
Jan 31, 2024
Initiates: Market Perform
Price Target: $37
Current: $74.52
Upside: -50.35%
Nov 3, 2023
Maintains: Outperform
Price Target: $102 → $100
Current: $53.81
Upside: +85.86%
Jun 17, 2022
Initiates: Outperform
Price Target: $98
Current: $50.99
Upside: +92.19%